(EVK) Evonik Industries - Overview
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE000EVNK013
Stock:
Total Rating 29
Risk 79
Buy Signal -1.68
| Risk 5d forecast | |
|---|---|
| Volatility | 39.5% |
| Relative Tail Risk | -4.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.52 |
| Alpha | -31.46 |
| Character TTM | |
|---|---|
| Beta | 0.328 |
| Beta Downside | 0.733 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.76% |
| CAGR/Max DD | -0.12 |
EPS (Earnings per Share)
Revenue
Description: EVK Evonik Industries
Evonik Industries AG produces and sells specialty chemicals in the Asia-Pacific, Europe, the Middle East, Africa, Central and South America, and North America. It operates through Specialty Additives, Nutrition & Care, Smart Materials, and Technology & Infrastructure segments. The Specialty Additives segment offers additives for polyurethane foams; additives, matting agents, fumed silicas, and specialty resins for paints, coatings, and printing inks; isophorone and epoxy curing agents for coatings, adhesives, and composites; and pour-point depressants and viscosity index improvers for coatings and oil and other lubricants for construction machinery and automotive sectors. The Nutrition & Care segment provides D-/l-methionine and lysine for animal nutrition industry; pharmaceutical active ingredients; medical products, including biocompatible and bioresorbable materials for orthopedic and medical applications; cell culture, such as pharmaceutical amino acids and peptides; and system solutions for the cosmetics and detergent industries. The Smart Materials segment offers inorganic materials, including fumed and precipitated silicas and silanes; peroxides for paper and textile industries; specialty catalysts for synthesis and alkoxides; and polymers products, such as polyamide 12, polymer foams, specialty polybutadiene and polyester, and membranes. The Technology & Infrastructure segment provides energy management, integrated plant support and maintenance, process safety and engineering, pipelines, transport management, logistics safety, digital solutions for chemical production, and strategic site development services. The company was founded in 1847 and is based in Essen, Germany.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 95.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -3.69 > 1.0 |
| NWC/Revenue: 13.02% < 20% (prev 10.46%; Δ 2.56% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.22b > Net Income 95.0m |
| Net Debt (4.04b) to EBITDA (1.78b): 2.27 < 3 |
| Current Ratio: 1.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (466.0m) vs 12m ago 0.30% < -2% |
| Gross Margin: 22.56% > 18% (prev 0.25%; Δ 2231 % > 0.5%) |
| Asset Turnover: 74.87% > 50% (prev 77.51%; Δ -2.64% > 0%) |
| Interest Coverage Ratio: 2.21 > 6 (EBITDA TTM 1.78b / Interest Expense TTM 217.0m) |
Altman Z'' 2.87
| A: 0.10 (Total Current Assets 5.30b - Total Current Liabilities 3.45b) / Total Assets 18.55b |
| B: 0.40 (Retained Earnings 7.41b / Total Assets 18.55b) |
| C: 0.03 (EBIT TTM 480.0m / Avg Total Assets 19.05b) |
| D: 0.71 (Book Value of Equity 7.18b / Total Liabilities 10.13b) |
| Altman-Z'' Score: 2.87 = A |
Beneish M -3.04
| DSRI: 0.97 (Receivables 1.67b/1.83b, Revenue 14.27b/15.16b) |
| GMI: 1.12 (GM 22.56% / 25.25%) |
| AQI: 1.01 (AQ_t 0.35 / AQ_t-1 0.34) |
| SGI: 0.94 (Revenue 14.27b / 15.16b) |
| TATA: -0.06 (NI 95.0m - CFO 1.22b) / TA 18.55b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of EVK shares?
As of March 05, 2026, the stock is trading at EUR 13.50 with a total of 2,170,413 shares traded.
Over the past week, the price has changed by -10.54%, over one month by +1.05%, over three months by +5.63% and over the past year by -25.73%.
Over the past week, the price has changed by -10.54%, over one month by +1.05%, over three months by +5.63% and over the past year by -25.73%.
Is EVK a buy, sell or hold?
Evonik Industries has no consensus analysts rating.
What are the forecasts/targets for the EVK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.1 | 11.6% |
| Analysts Target Price | - | - |
EVK Fundamental Data Overview March 02, 2026
Market Cap USD = 8.13b (6.89b EUR * 1.1794 EUR.USD)
P/E Trailing = 70.4286
P/E Forward = 19.9203
P/S = 0.4899
P/B = 0.8255
P/EG = 6.2284
Revenue TTM = 14.27b EUR
EBIT TTM = 480.0m EUR
EBITDA TTM = 1.78b EUR
Long Term Debt = 3.66b EUR (from longTermDebt, last quarter)
Short Term Debt = 830.0m EUR (from shortTermDebt, last quarter)
Debt = 4.49b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.04b EUR (from netDebt column, last quarter)
Enterprise Value = 10.93b EUR (6.89b + Debt 4.49b - CCE 454.0m)
Interest Coverage Ratio = 2.21 (Ebit TTM 480.0m / Interest Expense TTM 217.0m)
EV/FCF = 26.73x (Enterprise Value 10.93b / FCF TTM 409.0m)
FCF Yield = 3.74% (FCF TTM 409.0m / Enterprise Value 10.93b)
FCF Margin = 2.87% (FCF TTM 409.0m / Revenue TTM 14.27b)
Net Margin = 0.67% (Net Income TTM 95.0m / Revenue TTM 14.27b)
Gross Margin = 22.56% ((Revenue TTM 14.27b - Cost of Revenue TTM 11.05b) / Revenue TTM)
Gross Margin QoQ = 18.17% (prev 26.61%)
Tobins Q-Ratio = 0.59 (Enterprise Value 10.93b / Total Assets 18.55b)
Interest Expense / Debt = 1.25% (Interest Expense 56.0m / Debt 4.49b)
Taxrate = 44.70% (194.0m / 434.0m)
NOPAT = 265.4m (EBIT 480.0m * (1 - 44.70%))
Current Ratio = 1.54 (Total Current Assets 5.30b / Total Current Liabilities 3.45b)
Debt / Equity = 0.54 (Debt 4.49b / totalStockholderEquity, last quarter 8.35b)
Debt / EBITDA = 2.27 (Net Debt 4.04b / EBITDA 1.78b)
Debt / FCF = 9.88 (Net Debt 4.04b / FCF TTM 409.0m)
Total Stockholder Equity = 8.76b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.50% (Net Income 95.0m / Total Assets 18.55b)
RoE = 1.08% (Net Income TTM 95.0m / Total Stockholder Equity 8.76b)
RoCE = 3.86% (EBIT 480.0m / Capital Employed (Equity 8.76b + L.T.Debt 3.66b))
RoIC = 2.69% (NOPAT 265.4m / Invested Capital 9.85b)
WACC = 4.58% (E(6.89b)/V(11.39b) * Re(7.12%) + D(4.49b)/V(11.39b) * Rd(1.25%) * (1-Tc(0.45)))
Discount Rate = 7.12% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 86.56% ; FCFF base≈706.6m ; Y1≈723.0m ; Y5≈801.6m
[DCF] Fair Price = 42.51 (EV 23.85b - Net Debt 4.04b = Equity 19.81b / Shares 466.0m; r=5.90% [WACC]; 5y FCF grow 2.21% → 2.90% )
EPS Correlation: -34.71 | EPS CAGR: -35.13% | SUE: 0.65 | # QB: 0
Revenue Correlation: -82.32 | Revenue CAGR: -4.88% | SUE: -0.53 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.33 | Chg7d=-0.010 | Chg30d=-0.010 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=1.16 | Chg7d=+0.024 | Chg30d=-0.022 | Revisions Net=+2 | Growth EPS=-14.6% | Growth Revenue=+0.2%
EPS next Year (2027-12-31): EPS=1.37 | Chg7d=+0.043 | Chg30d=-0.011 | Revisions Net=+0 | Growth EPS=+17.6% | Growth Revenue=+2.3%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.5% (Discount Rate 7.9% - Earnings Yield 1.4%)
[Growth] Growth Spread = -5.3% (Analyst 1.2% - Implied 6.5%)
P/E Trailing = 70.4286
P/E Forward = 19.9203
P/S = 0.4899
P/B = 0.8255
P/EG = 6.2284
Revenue TTM = 14.27b EUR
EBIT TTM = 480.0m EUR
EBITDA TTM = 1.78b EUR
Long Term Debt = 3.66b EUR (from longTermDebt, last quarter)
Short Term Debt = 830.0m EUR (from shortTermDebt, last quarter)
Debt = 4.49b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.04b EUR (from netDebt column, last quarter)
Enterprise Value = 10.93b EUR (6.89b + Debt 4.49b - CCE 454.0m)
Interest Coverage Ratio = 2.21 (Ebit TTM 480.0m / Interest Expense TTM 217.0m)
EV/FCF = 26.73x (Enterprise Value 10.93b / FCF TTM 409.0m)
FCF Yield = 3.74% (FCF TTM 409.0m / Enterprise Value 10.93b)
FCF Margin = 2.87% (FCF TTM 409.0m / Revenue TTM 14.27b)
Net Margin = 0.67% (Net Income TTM 95.0m / Revenue TTM 14.27b)
Gross Margin = 22.56% ((Revenue TTM 14.27b - Cost of Revenue TTM 11.05b) / Revenue TTM)
Gross Margin QoQ = 18.17% (prev 26.61%)
Tobins Q-Ratio = 0.59 (Enterprise Value 10.93b / Total Assets 18.55b)
Interest Expense / Debt = 1.25% (Interest Expense 56.0m / Debt 4.49b)
Taxrate = 44.70% (194.0m / 434.0m)
NOPAT = 265.4m (EBIT 480.0m * (1 - 44.70%))
Current Ratio = 1.54 (Total Current Assets 5.30b / Total Current Liabilities 3.45b)
Debt / Equity = 0.54 (Debt 4.49b / totalStockholderEquity, last quarter 8.35b)
Debt / EBITDA = 2.27 (Net Debt 4.04b / EBITDA 1.78b)
Debt / FCF = 9.88 (Net Debt 4.04b / FCF TTM 409.0m)
Total Stockholder Equity = 8.76b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.50% (Net Income 95.0m / Total Assets 18.55b)
RoE = 1.08% (Net Income TTM 95.0m / Total Stockholder Equity 8.76b)
RoCE = 3.86% (EBIT 480.0m / Capital Employed (Equity 8.76b + L.T.Debt 3.66b))
RoIC = 2.69% (NOPAT 265.4m / Invested Capital 9.85b)
WACC = 4.58% (E(6.89b)/V(11.39b) * Re(7.12%) + D(4.49b)/V(11.39b) * Rd(1.25%) * (1-Tc(0.45)))
Discount Rate = 7.12% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 86.56% ; FCFF base≈706.6m ; Y1≈723.0m ; Y5≈801.6m
[DCF] Fair Price = 42.51 (EV 23.85b - Net Debt 4.04b = Equity 19.81b / Shares 466.0m; r=5.90% [WACC]; 5y FCF grow 2.21% → 2.90% )
EPS Correlation: -34.71 | EPS CAGR: -35.13% | SUE: 0.65 | # QB: 0
Revenue Correlation: -82.32 | Revenue CAGR: -4.88% | SUE: -0.53 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.33 | Chg7d=-0.010 | Chg30d=-0.010 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=1.16 | Chg7d=+0.024 | Chg30d=-0.022 | Revisions Net=+2 | Growth EPS=-14.6% | Growth Revenue=+0.2%
EPS next Year (2027-12-31): EPS=1.37 | Chg7d=+0.043 | Chg30d=-0.011 | Revisions Net=+0 | Growth EPS=+17.6% | Growth Revenue=+2.3%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.5% (Discount Rate 7.9% - Earnings Yield 1.4%)
[Growth] Growth Spread = -5.3% (Analyst 1.2% - Implied 6.5%)